Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study
Cureus · 21.09.2026
DOI: 10.7759/cureus.116644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 21.09.2026. Verfasst von Ana Luca Quintero und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Vacunar Panama, Panama, PAN. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Panama introduced routine maternal bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination (Abrysvo, Pfizer Inc., New York, NY) in July 2025. We described common retrospectively self-reported reactions and maternal, perinatal, and neonatal conditions among the first 200 eligible recipients enrolled in active follow-up. METHODS: This retrospective descriptive cohort included women aged 18 years or older who received RSVpreF at 32.0-36.6 weeks of gestation from July through December 2025 and completed one structured interview, generally after delivery, from January through July 2026. Exact vaccination-to-interview intervals were unavailable. Frequencies and Wilson 95% confidence intervals were calculated. RESULTS: Of 225 completed questionnaires, 200 met the eligibility criteria. The mean maternal age was 28.1 years (standard deviation = 6.4). Any reaction was reported by 55.5% (95% CI: 48.6%-62.2%), most often injection-site pain (48.0%), and self-reported fever occurred in 2.5%. A participant-reported hypertensive disorder occurred in 12.0%. Four births were preterm (2.0%), and five newborns had low birth weight (2.5%). Participant-reported jaundice was the most frequent neonatal condition (20.0%). CONCLUSIONS: Reported reactions were mainly local and short-lived. These findings describe early implementation in Panama but do not assess vaccine effectiveness, comparative safety, rare-event risk, or causality. Convenience recruitment, post-delivery selection, retrospective recall, absence of clinical verification and a comparator, and missing baseline risk and event-timing data limit interpretation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatrics, Vacunar Panama, Panama, PAN.
- Department of Population Intelligence and Scientific Advancement, Endpoints Research Sites Network & CEVAXIN, Panama, PAN.
- Faculty of Medicine, Universidad de Panamá, Panama, PAN.
- Pediatrics, Pediatrics Clinic Panama, Panama, PAN.
- Population Intelligence and Biostatistics, Cevaxin, Panama, PAN.
- Faculty of Medicine, School of Public Health, Universidad de Panamá, Panama, PAN.
Zitieren
APA
Luca Quintero, A., DeAntonio, R., Fernandez Camargo, I., Peralta Alvarado, A., Escobar, L., Ricci Perez, B., Flores, L. A., Gadea, C., Barrios, S., Guillen, E., De Avila, A., & Sevillano Giraldez, J. R. (2026). Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study. Cureus. https://doi.org/10.7759/cureus.116644
Vancouver
Luca Quintero A, DeAntonio R, Fernandez Camargo I, Peralta Alvarado A, Escobar L, Ricci Perez B, et al. Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study. Cureus. 2026. doi:10.7759/cureus.116644
BibTeX
@article{LucaQuintero2026,
author = {Luca Quintero, Ana and DeAntonio, Rodrigo and Fernandez Camargo, Isaac and Peralta Alvarado, Ana and Escobar, Luis and Ricci Perez, Belen and Flores, Luis Alberto and Gadea, Cynthia and Barrios, Sofia and Guillen, Emmanuel and De Avila, Abigail and Sevillano Giraldez, Jaime Ricardo},
title = {Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.116644}
}
EUVIMED